Revatis S.A. • Technologies • Gentle and minimally invasive technologies for obtaining multipotent mesenchymal stem cells and exosomes with high immunomodulatory potential
Stem cells are truly multipotent and exhibit exceptional paracrine properties
Adult stem cells are usually considered to have a limited potential for differentiation. Bone marrow and adipose tissue are the two most commonly used sources. Unfortunately, taking samples from these is more invasive, risky and painful.
Human health, Animal Health
Muscle microbiopsy
This is a minimally invasive procedure that uses a fine diameter (16G) biopsy needle. This allows the collection of 15 to 20 mg of tissue through a small skin puncture performed after local anesthesia and strict asepsis of the skin. The sample is placed in a specific medium, maintained between 4 and 8 degrees and sent to the production laboratory.
Human health, Animal Health
Cell culture
The micro-biopsies are sent to the laboratory within an ideal period of 48 to 72 hours, the samples are incubated in a specific culture medium. Progenitor cells develop from the biopsies. The fraction of interest is then isolated by centrifugation in a density gradient and amplified until the required number of cells is reached.
Human health, Animal Health
Production in aseptic isolator
Stem cell production takes place in an aseptic isolator, the procedure, which involves a Quality Management System (QMS), and Electronic Batch Record (EBR) is compliant with GMP standards. This system can be transferred to other production units while guaranteeing identical production quality.
Human health, animal health
Exosome production
The production of exosomes and/or extracellular vesicles (EVs) from muscle derived stem cells is carried out in an aseptic isolator to meet GMP standards using a gentle, innovative and efficient method. The released EVs possess regenerative, immunomodulatory and antibacterial properties.
Intellectual properties and know-how
Revatis holds an exclusive license for all human and veterinary applications of a patent granted in many countries which protects the method of collecting and culturing stem cells. Support for continuing R&D programs has enabled Revatis to file for other patents thus strengthening its intellectual property rights.
mammalian muscle-derived stem cells
WO2015091210 A1
The present invention provides a new method of obtaining muscle-derived mesenchymal stem cells from microbiopsies of mammalian origin. The invention provides for a minimally invasive methodology yielding high amounts of MSCs that can differentiate into different cell lineages.
New uses of mammalian muscle-derived stem cells
WO2018189121
The present invention relates to a method for assessing the effects of a compound or mixture on a mammal. This involves obtaining mammalian multipotent muscle-derived mesenchymal stem cells or a population thereof, exposing them to the relevant compound or mixture and assessing the effects on the cells. This invention provides for a reliable assessment method applicable to drug development, toxicity testing and optimized personalized medicine.
Method for obtaining differentiated cells from muscle-derived progenitor cells
WO2018189124
The present invention relates to a method for preparing differentiated mammalian cells collected by muscle microbiopsy, placing the sample in a cell culture medium, collecting and growing the cells and differentiating them in suitable differentiation medium.
Partnerships
Looking for collaborations in an innovative field?